UBS Group
ELTX icon

UBS Group’s Elicio Therapeutics ELTX Stock Holding History

UBS Group’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$430K Buy
236,038
+195,619
+484% +$543K ﹤0.01% 6267
2026
Q2 		$158K Buy
40,419
+6,650
+20% +$66.8K ﹤0.01% 6930
2026
Q1 		$361K Buy
33,769
+1,753
+5% +$16.9K ﹤0.01% 6306
2025
Q4 		$255K Buy
32,016
+24,997
+356% +$227K ﹤0.01% 6454
2025
Q3 		$76.8K Buy
7,019
+996
+17% +$10.1K ﹤0.01% 7283
2025
Q2 		$46.5K Sell
6,023
-15,175
-72% -$94.4K ﹤0.01% 7831
2025
Q1 		$131K Buy
21,198
+21,181
+124,594% +$164K ﹤0.01% 6837
2024
Q4 		$87 Sell
17
-831
-98% -$4.09K ﹤0.01% 9666
2024
Q3 		$4.27K Buy
848
+831
+4,888% +$3.68K ﹤0.01% 8162
2024
Q2 		$70 Buy
17
+1
+6% +$8 ﹤0.01% 9206
2024
Q1 		$122 Hold
16
– – ﹤0.01% 8806
2023
Q4 		$133 Hold
16
– – ﹤0.01% 8888
2023
Q3 		$135 Sell
16
-629
-98% -$5.99K ﹤0.01% 8810
2023
Q2 		$6.13K Sell
645
-804
-55% -$7.38K ﹤0.01% 7394
2023
Q1 		$8.41K Buy
1,449
+457
+46% +$3.05K ﹤0.01% 7728
2022
Q4 		$8.04K Buy
992
+268
+37% +$2.44K ﹤0.01% 8826
2022
Q3 		$7K Sell
724
-373
-34% -$3.9K ﹤0.01% 8862
2022
Q2 		$12K Buy
1,097
+1,050
+2,234% +$16.8K ﹤0.01% 7648
2022
Q1 		$1K Sell
47
-807
-94% -$18.2K ﹤0.01% 9862
2021
Q4 		$25K Buy
+854
New +$43.2K ﹤0.01% 7580
2021
Q3 		– Sell
-22
Closed -$3K – 9672
2021
Q2 		$3K Sell
22
-141
-87% -$20.3K ﹤0.01% 8794
2021
Q1 		$29K Buy
+163
New +$31.5K ﹤0.01% 7037

Other funds holding ELTX

Shah Capital Management
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group's ELTX Position: Q3 2026 in Review

UBS Group increased its Elicio Therapeutics (ELTX) stake by 484% in Q3 2026, buying an estimated $543K and bringing the position to 236,038 shares worth $430K. The position accounts for ﹤0.01% of the portfolio, ranked #6267.

UBS Group first reported a position in ELTX in Q1 2021 and has held it in 22 quarters since. 57 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

  • UBS Group held 236,038 shares of Elicio Therapeutics worth $430K as of Q3 2026.
  • UBS Group bought 195,619 Elicio Therapeutics shares in Q3 2026, an estimated $543K.
  • Elicio Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #6267 holding.
  • UBS Group first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • 57 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.